Phase 1 Study of Quizartinib
This is a dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of quizartinib for Japanese acute myeloid leukemia (AML) subjects.
Relapsed AML|Refractory AML
DRUG: AC220
number of subjects experiencing adverse events, first dose to follow-up, approximately 1 year|Cmax of quizartinib and its active metabolite, Evaluate the pharmacokinetics of quizartinib and its active metabolite, AC886 by Cmax, Tmax, AUCtau, Cmax,ss, Ctrough, Tmax,ss, AUCtau,ss., Cycle 1: Days 1, 2, 4, 8, 11, 15, 16, 18, 22, 28; Cycle 2 and on: Days 1, 15|Tmax of quizartinib and its active metabolite, Evaluate the pharmacokinetics of quizartinib and its active metabolite, AC886 by Cmax, Tmax, AUCtau, Cmax,ss, Ctrough, Tmax,ss, AUCtau,ss., Cycle 1: Days 1, 2, 4, 8, 11, 15, 16, 18, 22, 28; Cycle 2 and on: Days 1, 15|AUCtau of quizartinib and its active metabolite, Evaluate the pharmacokinetics of quizartinib and its active metabolite, AC886 by Cmax, Tmax, AUCtau, Cmax,ss, Ctrough, Tmax,ss, AUCtau,ss., Cycle 1: Days 1, 2, 4, 8, 11, 15, 16, 18, 22, 28; Cycle 2 and on: Days 1, 15|Cmax,ss of quizartinib and its active metabolite, Evaluate the pharmacokinetics of quizartinib and its active metabolite, AC886 by Cmax, Tmax, AUCtau, Cmax,ss, Ctrough, Tmax,ss, AUCtau,ss., Cycle 1: Days 1, 2, 4, 8, 11, 15, 16, 18, 22, 28; Cycle 2 and on: Days 1, 15|Ctrough of quizartinib and its active metabolite, Evaluate the pharmacokinetics of quizartinib and its active metabolite, AC886 by Cmax, Tmax, AUCtau, Cmax,ss, Ctrough, Tmax,ss, AUCtau,ss., Cycle 1: Days 1, 2, 4, 8, 11, 15, 16, 18, 22, 28; Cycle 2 and on: Days 1, 15|Tmax,ss of quizartinib and its active metabolite, Evaluate the pharmacokinetics of quizartinib and its active metabolite, AC886 by Cmax, Tmax, AUCtau, Cmax,ss, Ctrough, Tmax,ss, AUCtau,ss., Cycle 1: Days 1, 2, 4, 8, 11, 15, 16, 18, 22, 28; Cycle 2 and on: Days 1, 15|AUCtau,ss of quizartinib and its active metabolite, Evaluate the pharmacokinetics of quizartinib and its active metabolite, AC886 by Cmax, Tmax, AUCtau, Cmax,ss, Ctrough, Tmax,ss, AUCtau,ss., Cycle 1: Days 1, 2, 4, 8, 11, 15, 16, 18, 22, 28; Cycle 2 and on: Days 1, 15
FMS-like tyrosine kinase-3 / internal tandem duplication FLT3/ITD allelic ratio, Exploratory assessment of quizartinib-related biomarkers such as FLT3-ITD allelic ratio, PIA assessment., Cycle 1: Days 1, 2, 8, 15|PIA assessment, Exploratory assessment of quizartinib-related biomarkers such as FLT3-ITD allelic ratio, PIA assessment., Cycle 1: Days 1, 2, 8, 15|bone marrow findings, Exploratory analyses of tumor response to quizartinib based on bone marrow findings, absolute neutrophil count, and platelet count., Cycle 1: Days 15, 28; Cycle 2 and on: Day 28|absolute neutrophil count, Exploratory analyses of tumor response to quizartinib based on bone marrow findings, absolute neutrophil count, and platelet count., Cycle 1: Days 15, 28; Cycle 2 and on: Day 28|platelet count, Exploratory analyses of tumor response to quizartinib based on bone marrow findings, absolute neutrophil count, and platelet count., Cycle 1: Days 15, 28; Cycle 2 and on: Day 28
This is a dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of quizartinib for Japanese acute myeloid leukemia (AML) subjects.